Lilly's Zepbound tops Wegovy for weight loss

Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Zepbound brings more weight loss than Wegovy: Drugmaker
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from
Which Weight-Loss Drug Is Better: Wegovy or Zepbound?
W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its la
Zepbound leads to more weight loss than Wegovy, new study finds
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time. Zepbound,
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Health on MSN8h
Can’t Afford Ozempic, Other GLP-1 Drugs? Here’s What to Do, According to Experts
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
STAT10d
Trump’s pick to run FDA is top exec of company that provides compounded weight-loss drugs
Martin Makary, President-elect Trump’s pick for running the Food and Drug Administration, is an executive of the telehealth ...
Weight loss drug overdose calls rising, poison control centers say
Poison control centers around the country are warning about a rise in calls of patients overdosing on Ozempic.
Weight-loss drugs deliver life-changing health benefits - and big profits
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
The American Journal of Managed Care9d
FDA Advised to Update Labels on GLP-1 Weight-Loss Drugs
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...